Literature DB >> 3030940

Characterization of EBV-carrying B-cell populations in healthy seropositive individuals with regard to density, release of transforming virus and spontaneous outgrowth.

N Lewin, P Aman, M G Masucci, E Klein, G Klein, B Oberg, H Strander, W Henle, G Henle.   

Abstract

Peripheral or tonsil lymphocyte populations of EBV-seropositive donors give rise to EBV-carrying LCLs upon in vitro explantation. Such lines can arise either by a 2-step mechanism, namely release of virus from some of the explanted cells followed by infection of previously uninfected B cells, or by direct outgrowth of virus-harboring B cells (Rickinson et al., 1974; Dalens et al., 1975; Hinuma and Katsuki 1978; Katsuki et al., 1979). We observed that cells responsible for both the 2-step mechanism and for direct outgrowth are found in the purified B-cell compartment. Virus release was more frequent than direct outgrowth. The majority of virus-releasing cells were found in the low-density fraction that contains large, activated B blasts. Cells that were capable of spontaneous outgrowth in the presence of the viral inhibitor PFA and of virus-neutralizing antibody gave rise to cell lines that carried the sex chromosome marker of the original donor, rather than that of admixed cord blood lymphocyte of the opposite sex. Such cells were found in both the low- and the high-density fractions. The majority of the EBV-carrying B cells in vivo are thus low-density blasts. Rare small B cells of high density harboring EBV were capable of spontaneous outgrowth. This may be indicative of a host control mechanism that is removed upon cultivation in vitro.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3030940     DOI: 10.1002/ijc.2910390411

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  21 in total

Review 1.  The role of EBV in post-transplant malignancies: a review.

Authors:  P Hopwood; D H Crawford
Journal:  J Clin Pathol       Date:  2000-04       Impact factor: 3.411

2.  Quantitative analysis of latent human cytomegalovirus.

Authors:  B Slobedman; E S Mocarski
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

3.  Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes.

Authors:  L Qu; D T Rowe
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

4.  Epstein-Barr virus-encoded nuclear antigen 2 activates the viral latent membrane protein promoter by modulating the activity of a negative regulatory element.

Authors:  R Fåhraeus; A Jansson; A Ricksten; A Sjöblom; L Rymo
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

5.  Identification of type B-specific and cross-reactive cytotoxic T-lymphocyte responses to Epstein-Barr virus.

Authors:  B M Kerr; N Kienzle; J M Burrows; S Cross; S L Silins; M Buck; E M Benson; B Coupar; D J Moss; T B Sculley
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

6.  Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell.

Authors:  E M Miyashita; B Yang; G J Babcock; D A Thorley-Lawson
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

7.  Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EmuLMP2A transgenic mice.

Authors:  R G Caldwell; R C Brown; R Longnecker
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

8.  Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus.

Authors:  C Bogedain; H Wolf; S Modrow; G Stuber; W Jilg
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

9.  Epstein-Barr virus latent messages with shuffled leader exons: remnants of circumgenomic transcription?

Authors:  L Qu; D T Rowe
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

10.  5-Azacytidine up regulates the expression of Epstein-Barr virus nuclear antigen 2 (EBNA-2) through EBNA-6 and latent membrane protein in the Burkitt's lymphoma line rael.

Authors:  M G Masucci; B Contreras-Salazar; E Ragnar; K Falk; J Minarovits; I Ernberg; G Klein
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.